for a new $500 million plant, despite that country’s high labour costs and strong currency. The plant manufactures therapies based on research done by CSL in Australia.
“Most of our major competitors – Switzerland, the UK, India and Singapore for example - have IP [intellectual property] incentive tax rates, commonly known as a ‘patent box’. Many others are considering it too. “We have a gem in Adelaide, with the facility, the capability, the expertise. This is something we’re saying, we have the ability, we can help,” he said.
The federal government had asked him to approach Pfizer to see if it might be possible to secure an Australian licence, he said. “I clearly do have [Pfizer’s] ear and the inside track.”
liammannix How dare we have tight, stringent regulations, we should just let anyone have a go and stuff the process, we can trust them, their honest!!
liammannix Well that's it people, australia is not capable of manufacturing anything. Unless it comes out of the dirt or water and we can export it, we are useless 🤦♂️🤦♂️
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Источник: abcnews - 🏆 5. / 83 Прочитайте больше »